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Abstract
Nearly 40% of children with acute myeloid leukemia (AML) suffer relapse due to 
chemoresistance, often involving upregulation of the oncoprotein STAT3 (signal transducer and 
activator of transcription 3). In this paper, rhodium(II)-catalyzed, proximity-driven modification 
identifies the STAT3 coiled-coil domain (CCD) as a novel ligand-binding site, and we describe a 
new naphthalene sulfonamide inhibitor that targets the CCD, blocks STAT3 function, and halts its 
disease-promoting effects in vitro, in tumor growth models, and in a leukemia mouse model, 
validating this new therapeutic target for resistant AML.
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AML is an aggressive malignancy. Relapse is common, and relapsed tumors are typically 
chemoresistant, necessitating fundamentally new therapeutic approaches.[1] STAT3 signaling 
plays a key role in mediating drug resistance by halting apoptosis and increasing 
tumorigenicity.[2] As such, STAT3 is a tantalizing target for drug development, either alone 
or in combination with other chemotherapeutic agents. In this manuscript, we employ a new 
fingerprinting method—proximity-driven rhodium(II) catalysis—to identify a new inhibitor 
binding site within the coiled-coil domain (CCD) of STAT3. Furthermore, we describe an 
optimized compound that targets the coiled-coil domain of STAT3, inhibits STAT3 activity 
in cells and displays anti-leukemia activity in AML cells in culture and in vivo.
STAT3 is a multidomain protein that is activated by tyrosine phosphorylation (pY705) in 
response to cytokine–receptor binding (e.g. IL-6 binding to gp130). Reciprocal 
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intermolecular interactions between the C-terminal loop (containing pY705) and the Src 
homology 2 (SH2) domain facilitate homodimerization (see Fig. 4 for structure). This 
dimerization drives STAT3 accumulation in the nucleus, DNA binding to the DNA-binding 
domain, and oncogene transcriptional activation. STAT3 also contains a 4-helix CCD, 
connecting the DNA-binding and SH2 domains to an N-terminal oligomerization domain. 
Upregulated STAT3 activation was first reported in cells transformed by the oncogene v-
src,[3] and fibroblasts with constitutively-active STAT3 (STAT3-C) developed malignant 
properties and form tumors in nude mice.[4]
STAT3 presents the classic problems of “undruggable” protein-protein interfaces. Efforts 
have typically involved molecules that bind the SH2 domain, mimicking phosphotyrosine 
interactions,[2, 5–11] though inhibitors of other STAT proteins apparently not involving the 
SH2 domain have appeared.[12] Our understanding of STAT3 function makes clear that 
disrupting SH2–phosphopeptide interactions necessary for dimerization will disrupt STAT3 
function, and SH2 interactions are essential for STAT3 phosphorylation by upstream 
kinases. However, the discovery of cell-permeable small-molecule SH2 inhibitors has 
proven challenging. Beyond the SH2 and DNA-binding domains, other STAT3 domains are 
relatively unique, and little is known of their function or potential as drug targets.
We identified compelling naphthalene sulfonamides with activity against STAT3, including 
an initial lead compound (C188, Fig. 1),[13] and compounds from structural optimization, 
such as C188-9.[2] These compounds inhibit STAT3 binding to an immobilized pY-peptide 
in surface plasmon resonance (SPR) assays and exhibit other encouraging properties, 
including inhibition of STAT3 phosphorylation in cells, inhibition of STAT3-dependent gene 
transcription, and apoptosis induction in AML cell lines. We initially assumed that the 
activity of these compounds was due to direct binding to the SH2 domain, based on analogy 
to other STAT3 inhibition efforts and our own computational and medicinal chemistry 
efforts.
Further investigations suggested that C188-9 may bind to STAT3 at a site distinct from the 
SH2 domain. First, a few naphthalene sulfonamides inhibited pSTAT3–DNA binding (Fig. 
2), but DNA-binding inhibition is poorly correlated with phosphopeptide-binding inhibition. 
For example, C188 and MM-206 exhibit dose-dependent inhibition of DNA binding (IC50 = 
1–5 μM, Fig. 2c,d), similar to that observed for the SPR-based SH2 binding-inhibition assay. 
In contrast, C188-9 also inhibits STAT3 binding to its pY-peptide ligand, yet has minimal 
ability to inhibit STAT3 binding to DNA (IC50 >30 uM), as judged by an SPR-based assay 
of DNA–STAT3 interactions (c). Furthermore C188-9 and other successful inhibitors have 
no charge, in contrast to the anionic structure most SH2 small-molecule inhibitors, which 
mimic a phosphotyrosine dianion. The presumed SH2 domain target—with a prominent 
cysteine (Cys712) immediately flanking the binding pocket—should be a fruitful target for 
rhodium(II) conjugates as STAT3 inhibitors. We also failed in attempts to employ rhodium 
conjugates of naphthalene sulfonamides to improve affinity through rhodium coordination to 
Lewis-basic side chains found near the SH2 domain.[14–15] While metalloinhibitors failed to 
deliver on their intended purpose, they facilitated our identification of an allosteric binding 
site as a new target site for STAT3 inhibitors.
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Rhodium(II) conjugates catalyze reactions of diazo compounds with biomolecules,[16–18] via 
a metallocarbene intermediate. We previously discovered rhodium–peptide conjugates for 
protein functionalization,[19] and sought to extend these ideas to STAT3 and to small-
molecule ligands, where covalent modification might serve to identify the site of binding of 
naphthalene sulfonamides. Among several advantages, the method allows biologically-
relevant concentrations of a ligand–catalyst, has minimal spurious background labeling, and 
succeeds for weak, transient interactions. Importantly, the rhodium(II) core does not 
significantly alter STAT3–small molecule interactions. The rhodium complex, C188-9-Rh2, 
has in vitro potency similar to that of C188-9 in the SPR assays discussed above, and also 
inhibits STAT3 phosphorylation in cells and induces apoptosis in AML cell lines (Fig. S3).
To examine rhodium-catalyzed proximity-driven labeling, STAT3 was treated with a 
rhodium-inhibitor conjugate, C188-9-Rh2 (1 μM) in the presence of excess diazo 1 (1 mM) 
(Fig. 3). Negative control experiments, such as reactions catalyzed by Rh2(OAc)4, showed 
minimal modification by diazo reagents, as judged by fluorescent imaging of a blot 
membrane with a fluorogenic dye (3-azido-7-hydroxycoumarin) and a copper catalyst.[19] In 
contrast, reactions catalyzed by C188-9-Rh2 gave a strongly fluorescent STAT3 band after 
azide–alkyne coupling of a fluorogenic azide, indicative of clean modification. Of note, 
modification of monomeric STAT3 or dimeric pSTAT3 occured with equal facility. Tryptic 
digestion of the modified STAT3 allowed identification of the site of modification by LC–
MS/MS methods (see SI for details). We observed a single new peak with a mass (m+ = 
2160.99) consistent with a single modification of an expected digest peptide, Val164–
Lys177 (Fig. 3c,d). The identity of this digest peptide could be further confirmed—and the 
specific site of modification identified—by MS/MS fragmentation of the +1 mod peak. As 
shown in Fig. 3e, sufficient coverage of b and y ions was observed to conclusively identify 
phenylalanine (Phe174) as the site of modification. Phenylalanine was previously identified 
as an efficient reaction site in rhodium-conjugate-catalyzed side-chain modifications.[20]
The modified Phe174 residue sits in the coiled-coil domain (CCD, Fig. 4), quite distal from 
the expected SH2 domain. We found no evidence for modification of other residues, within 
the SH2 domain or elsewhere. Modification of Phe174 was inhibited in the presence of 
MM-206, C188-9, or C188 (Fig. 3b, lanes e–g, j, l), indicating that other naphthalene 
sulfonamide compounds compete directly for the CCD binding site. In stark contrast, a 
phosphopeptide SH2 ligand has no effect on the modification (lanes d, k), indicating that 
SH2 ligands have minimal impact on the distal CCD domain. Similar inhibition was 
observed with dimeric pSTAT3, which has no accessible SH2 domain. Thus, in addition to 
identifying the CCD as the site of binding, rhodium-conjugate catalytic modification serves 
as a direct tool to probe for and establish CCD binding by other inhibitors.
The identification of a unique CCD binding site, while unexpected, is consistent with 
disparate and puzzling previous observations, including the limited correlation between 
DNA- and phosphopeptide-binding inhibition. Most compellingly, covalent labeling of the 
coiled-coil domain with the rhodium-conjugate catalyst is independent of STAT3 
dimerization state. Were rhodium-conjugates interacting with the SH2 domain, significantly 
diminished modification would be expected in the dimeric (phosphorylated) state. Instead, 
modification efficiency was indistinguishable comparing monomeric STAT3 with 
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phosphorylated dimeric protein that presumably has no available SH2 binding sites (Fig. 
3b). Additionally, binding to the coiled-coil domain near Phe174 provides a rationale for the 
failure of rhodium conjugates to deliver improved STAT3 inhibitory activity due to Lewis-
basic coordination (with Met/Cys/His): the coiled coil surface is devoid of Lewis-basic side 
chains (Fig. 4b).
In 2000, a study[21] described STAT3 mutations within the CCD and presented results that 
now appear remarkably consistent with our findings. Two examples of STAT3 proteins with 
a point mutation in the coiled-coil domain had drastically lower SH2-mediated affinity for 
phosphopeptide recognition sequences in gp130 and EGFR, and these mutants had 
drastically lower STAT3 phosphorylation stimulated by these receptors.[21] The key residue 
in the CCD, a point mutant of which exerted the largest effect on STAT3 activity and 
specifically SH2 affinity, was Asp170. In a coiled coil, this key aspartate (Asp 170) lies one 
helix turn away from—and thus directly neighbors—the Phe174 that we identified as near 
the site of naphthalene sulfonamide interactions (Fig. 4a, b). More recent structural data 
show that the STAT3 tertiary structure—with coiled-coil and SH2 domains on opposite sides 
of the protein—remains constant regardless of phosphorylation or dimerization state.[22–24] 
Both the mutants[21] and the results described here point to the coiled-coil surface around 
Asp170 and Phe174 as crucial for STAT3 function, with point mutations or small-molecule 
binding having profound effects on the function of the distal SH2 domain. However, it 
remains for future studies to establish how selective inhibitors of the coiled-coil domain 
might be. From a drug-development perspective, there may be distinct advantages to 
targeting domains other than SH2, a large domain family present throughout the 
genome.[25–27]
Targeting the STAT3 CCD is relevant in models of acute myeloid leukemia (AML). From a 
brief study synthesizing derivatives of the C188 lead, fluorinated MM-206 (Fig. 1) stood out 
as a promising candidate. The perfluorophenylsulfonamide group, which has appeared in 
clinical trials without apparent toxicity concerns,[28–31] was suggested by another STAT3 
inhibitor effort.[6] In the SPR-based competitive binding assay (Fig. 2a), MM-206 had IC50 
= 1.2 μM, lower than previous-generation inhibitors such as C188 (IC50 = 7.2 μM) and 
C188-9 (IC50 = 5.0 μM). The inhibitor MM-206 also inhibits inducible STAT3 
phosphorylation in AML cell lines (Fig. 5a,b). Following a 30-minute treatment with 
MM-206 prior to G-CSF stimulation, all three AML cell lines tested exhibited dose-
dependent decreases in STAT3 phosphorylation with IC50 0.8–1.9 μM.
To evaluate the therapeutic potential of this new agent, we confirmed its ability to induce 
apoptosis in AML cell lines and primary tumor cells from pediatric AML patients. A 24-
hour treatment with MM-206 increased apoptosis in all AML cell lines and primary samples 
tested (n = 4, Fig. 5c). Cell viability assays with luciferase-transduced AML cell lines 
provided similar results. (Fig. S2). In contrast, acute lymphoblastic leukemia (ALL) cell 
lines—which do not have upregulated STAT3 activity[32]—were much less sensitive to 
apoptosis induction (Fig. 5c, KOPN-8 and RS4-11), consistent with a STAT3-based 
mechanism of action.
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Finally, we engrafted immunocompromised NOD-SCID-IL2Rγ−/− (NSG) mice with 
luciferase-expressing MV4-11 AML cells. After 2 weeks, mice were treated for two weeks 
(10 doses).
Treated cells showed lower luminescence at week 5 relative to control, indicating delayed 
disease progression. Disease did progress rapidly once treatment stopped, so we tested a 4-
week regimen. Again, treament slowed disease progression. Further, there was a significant 
decrease in the percent of tumor cells in the bone marrow of treated mice (Fig. 5d), and 
treated mice had significantly prolonged survival (p=0.019 at 10 weeks; Fig. 5e).
Relatively little is known about the functional role of the STAT3 coiled coil. However, on the 
basis of data from just a few CCD-domain mutants, Cao made a prescient comment that 
“coiled-coil region of STAT3 may be a useful target for drug design.”[21] This work validates 
that prediction. It now appears that the N-terminal domain engages in action-at-a-distance, 
playing a crucial role conveying information between the N-terminal and C-terminal 
domains, akin to coiled-coil transmembrane domains in extracellular receptors. The inhibitor 
MM-206 serves as a tool to better understand STAT3 biology, and also validates the CCD as 
a therapeutic target. Identification of the CCD binding site is made possible by proximity-
driven rhodium catalysis—used for the first time here to illuminate binding sites—and 
inhibition of catalytic modification directly assesses the binding of other STAT3 ligands.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Structures of selected STAT3 inhibitors.
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Figure 2. 
(a,b) SPR measurement of STAT3 inhibition. STAT3 binding to an immobilized 
phosphopeptide inhibited by naphthalene sulfonamide inhibitors C188-9 (a) and MM-206 
(b). (c) DNA-binding inhibition, measured by SPR. (d) Quantification of DNA-binding 
inhibition of MM-206.
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Figure 3. 
(a) Scheme of affinity labeling catalyzed by rhodium(II) conjugates. Recombinant STAT3 
(no N-terminal domain, 2 μM) was treated with C188-9-Rh2 (0.5 μM) and diazo 1 (700 μM) 
in pH 7.4 HEPES. For pSTAT labeling, pSTAT3 (1 μM) and C188-9-Rh2 (1 μM) were used. 
(b) Blot analysis (3-azido-7-hydroxycoumarin and a copper catalyst) of reactions in the 
presence of other STAT3 inhibitors. Surface cysteine was blocked with iodoacetimide prior 
to rhodium reactions. Rxn time for STAT3 = 6 h, for pSTAT3 = 14 h. (c) Extracted ion 
chromatogram (EIC) of tryptic digest for modified STAT3 for the Val164–Lys177 peptide 
(m = 1745.80) and +1mod (m = 2160.99). (d) MS spectra at tr = 16.9 min. (e) LC–MS/MS 
analysis of the Phe174-modified Val164–Lys177 peptide, with expected y and b ions, 
Daughter ions in bold matched to ±10 ppm.
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Figure 4. 
(a) Structure of the pSTAT3 dimer: SH2 domain at the top, bound to a phosphopeptide 
ligand (wireframe) of the complementary molecule. The central DNA-binding domain 
bound to dsDNA (orange). The CCD is shown in the inset, with the site of rhodium-
catalyzed labeling (Phe174) in purple and the Asp170 residue (green), identified previously 
as a residue controlling STAT3 function. See text for discussion. (b) STAT3 coiled-coil 
region, indicating a lack of Lewis-basic (H, M, C) residues (orange).
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Figure 5. 
MM-206 inhibits G-CSF-induced STAT3 phosphorylation, induces apoptosis in human 
AML cells, and slows disease progression in a xenograft model of AML. (a) Histogram of 
decrease in pSTAT3 in Kasumi-1 cells. (b) MM-206 inhibits G-CSF-induced pY-STAT3 in 
multiple AML cell lines. Legend values indicate IC50 values. Mean ±SD for n = 3. (c) 
Apoptosis quantified in Annexin V-FITC-labeled cells treated with MM-206 for 24 h. 
Spontaneous apoptosis in untreated cells was subtracted to yield the % apoptosis attributable 
to drug. Data shown for an AML cell line (MV4-11, HL-60) and primary patient-derived 
AML cells (p198) compared to ALL cell lines (KOPN-8, RS4-11) as a negative control. (d–
f) NSG mice were injected iv with 107 MV4-11.ffluc AML cells at day 0. After two weeks, 
mice received MM-206 (30 mg/kg or vehicl0065), ip daily 5 days per week for 2 weeks 
(weeks 2–4) or 4 weeks (weeks 2–6). (d) At the time of death, bone marrow was collected 
and the percentage of human (diseased) AML cells in mouse marrow present was 
determined as a measure of diease progression. *P<0.05. (e) Kaplan-Meier survival curve 
shows significantly longer survival for mice treated for 4 weeks. (f) Luminescence images 
one week after treatment. Colorized signal intensity indicates amount of active disease, from 
low (blue) to high (red).
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